Blockchain Registration Transaction Record

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

Helus Pharma appoints Dr. Suresh Durgam to board, bolstering CNS pipeline. Learn how his FDA approval expertise supports late-stage development of NSAs for depression and anxiety.

This news matters because the appointment of Dr. Suresh Durgam, a seasoned CNS drug development expert with a proven track record at Intra-Cellular Therapies, significantly strengthens Helus Pharma's leadership as it advances its pipeline of novel serotonergic agonists. With HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, Helus Pharma is positioned to potentially bring new, more effective treatments to millions suffering from mental health conditions. Durgam's experience in securing FDA approvals for CAPLYTA across multiple indications will be invaluable in navigating the regulatory landscape and accelerating the path to commercialization. For investors, this strategic addition to the board could enhance the company's credibility and drive value, while for patients, it signals hope for innovative therapies that address unmet needs in depression and anxiety.